Colchicine

As Americans, Including President Donald J. Trump, Test Positive for COVID-19, the COLCORONA Trial Opens More Enrollment Sites Across the United States and Internationally

Retrieved on: 
월요일, 10월 5, 2020
Clinical research, Health, Medical research, Articles, Design of experiments, Orphan drugs, Drug discovery, Pharmaceutical industry, Colchicine, Clinical trial, Placebo-controlled study, Placebo

NEW YORK, Oct. 5, 2020 /PRNewswire/ -- With rising numbers of Americans testing positive forCOVID-19, including President Trump, the COLCORONA trial adds enrollment sites in the United States and including locations in Mississippi, Arizona, Minnesota, South Carolina, North Carolina and Florida.

Key Points: 
  • NEW YORK, Oct. 5, 2020 /PRNewswire/ -- With rising numbers of Americans testing positive forCOVID-19, including President Trump, the COLCORONA trial adds enrollment sites in the United States and including locations in Mississippi, Arizona, Minnesota, South Carolina, North Carolina and Florida.
  • The international COLCORONA clinical trial is evaluating colchicine, a common drug for gout, as a potential treatment to reduce severity of illness, complications, and hospitalizations due to COVID-19.
  • COLCORONA is a contact-free, at-home, randomized, double-blind, placebo-controlled study conducted in the United States,Canada, South America, Europe, andSouth Africa.
  • The MHICC possesses an established network of collaborators in over 4500 clinical sites in more than 40 countries.

Pharmascience Inc. reiterates its support to the Montreal Heart Institute's colchicine repurposing research studies in cardiovascular medicine and COVID-19

Retrieved on: 
월요일, 8월 31, 2020
Organic compounds, Drugs, Colcot, Colchicine, Chemical compounds

The first of these sub analyses was simultaneously published in the European Heart Journal (EHJ).

Key Points: 
  • The first of these sub analyses was simultaneously published in the European Heart Journal (EHJ).
  • The second sub analysis found credible genetic associationswith CV endpoints and gastrointestinal events in patients treated with colchicine in COLCOT.
  • Pharmascience Inc. is proud of its continued collaboration with the MHI's Research Center, which led in 2019 to the landmark COLCOT I trial.
  • These studies are indicative of major potential positive impacts on the cardiovascular outcomes of patients and public health in general.

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

Retrieved on: 
토요일, 8월 29, 2020
RTT, Drugs, Health, Acetamides, Alkaloids, Colchicine, Polypharmacy, Myocardial infarction, Colcot

Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.

Key Points: 
  • Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.
  • In addition to these meaningful results from COLCOT, colchicine is also being evaluated in the COLCORONA clinical trial.
  • Time-to-treat initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
  • Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT), Eur Heart J Qual Care Clin Outcomes.

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

Retrieved on: 
토요일, 8월 29, 2020
RTT, Drugs, Health, Acetamides, Alkaloids, Colchicine, Polypharmacy, Myocardial infarction, Colcot

Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.

Key Points: 
  • Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.
  • In addition to these meaningful results from COLCOT, colchicine is also being evaluated in the COLCORONA clinical trial.
  • Time-to-treat initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
  • Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT), Eur Heart J Qual Care Clin Outcomes.

Nearly Half of Americans Surveyed Willing to Consider Participating in Generic Drug Trials for COVID-19 Treatments Despite Testing Notification Delays up to Six Days

Retrieved on: 
일요일, 8월 23, 2020
Medical specialties, Health, Clinical medicine, RTT, Arthritis, Rheumatology, Alkaloids, Colchicine, Pericarditis, Gout, Clinical trial, Familial Mediterranean fever

Each of those studies concluded that we need quality, robust clinical trials like COLCORONA to definitively change clinical practice for colchicine usage."

Key Points: 
  • Each of those studies concluded that we need quality, robust clinical trials like COLCORONA to definitively change clinical practice for colchicine usage."
  • Non-hospitalized patients over 40 years old, diagnosed with COVID-19, can participate for free by calling the hotline at 1-877-536-6837.
  • Colchicine is a generic, orally administered anti-inflammatory medication that is currently indicated for the management of pericarditis, gout, and familial Mediterranean fever.
  • It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing.

Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

Retrieved on: 
금요일, 6월 12, 2020
Biotechnology, FDA, Pharmaceutical, Health, Articles, Organic compounds, Drugs, RTT, Acetamides, Alkaloids, Colchicine, Dr. Reddy's Laboratories, Generic drug, IQVIA

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).
  • The Colcrys brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
  • Dr. Reddys Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Montreal Heart Institute Colcorona Study receives grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation to investigate cheap, readily available drug

Retrieved on: 
화요일, 5월 12, 2020
Computer security software, Organic compounds, Drugs, Acetamides, Alkaloids, Colchicine, RTT, MHI, Alwaleed Philanthropies, Montreal Heart Institute, Avast, Mark Zuckerberg

MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) Research Center today announced a 3-million-dollar grant from the COVID-19 Therapeutics Accelerator for its innovative ColCorona COVID-19 clinical trial.

Key Points: 
  • MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) Research Center today announced a 3-million-dollar grant from the COVID-19 Therapeutics Accelerator for its innovative ColCorona COVID-19 clinical trial.
  • The hypothesis is that colchicine may prevent the phenomenon of major inflammatory storm responsible for severe complications seen in patients with COVID-19.
  • This is one of the few current studies of COVID-19 infection in which non-hospitalized individuals can participate.
  • COVID-19 Therapeutics Accelerator donors include the Bill & Melinda Gates Foundation, Wellcome, Mastercard, U.K. Department for International Development, Chan Zuckerberg Initiative, Michael & Susan Dell Foundation, Avast, Zhang Yiming, Alwaleed Philanthropies, EQT and Madonna.

Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session

Retrieved on: 
월요일, 3월 30, 2020
Medicine, Medical specialties, Clinical medicine, RTT, Colchicine, Pericarditis, C-reactive protein, Rilonacept, Corticosteroid

The analysis, which showed the corticosteroid-sparing effect of rilonacept treatment in the Phase 2 trial, was included in a virtual poster at theAmerican College of Cardiologys(ACC) 69th Annual Scientific Session.

Key Points: 
  • The analysis, which showed the corticosteroid-sparing effect of rilonacept treatment in the Phase 2 trial, was included in a virtual poster at theAmerican College of Cardiologys(ACC) 69th Annual Scientific Session.
  • Final data from the Phase 2 trial were presented at the American Heart Association (AHA) Scientific Sessions in November 2019.
  • Corticosteroid-dependent patients tapered or discontinued corticosteroids without pericarditis recurrence while on rilonacept treatment.
  • Colchicine-failure patients with active pericarditis experienced rapid, sustained and clinically meaningful reductions in pain and CRP while on rilonacept treatment.

Message of public interest: Clinical study for people infected with COVID-19

Retrieved on: 
금요일, 3월 27, 2020
RTT, Organic compounds, Drugs, Cardiology, Colchicine, Chemical compounds

The clinical study is a public service offered to anyone 40 years and older who has been diagnosed with COVID-19 and who is not hospitalized.

Key Points: 
  • The clinical study is a public service offered to anyone 40 years and older who has been diagnosed with COVID-19 and who is not hospitalized.
  • The study, called COLCORONA, aims to determine whether short-term treatment based on colchicine would reduce the risk of pulmonary complications and death related to COVID-19.
  • More specifically COLCORONA studies the phenomenon of major inflammatory storm present in adults suffering from severe complications related to COVID-19.
  • It is home to the largest cardiology research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in the country.

Avion Pharmaceuticals' new gout prophylaxis product, GLOPERBA®, is the first and only liquid form of colchicine (1,2)

Retrieved on: 
목요일, 2월 27, 2020
Medical specialties, Health, Medicine, RTT, Rheumatology, Dosage forms, Alkaloids, Colchicine, Gout, Arthritis, Tablet, Dose

Gout is a debilitating form of arthritis affecting an estimated 8.7 million people in the United States.

Key Points: 
  • Gout is a debilitating form of arthritis affecting an estimated 8.7 million people in the United States.
  • Prior to GLOPERBA, colchicine was only available in tablet and capsule forms, which can make dose adjustments difficult for patients.
  • As a liquid oral solution, GLOPERBA allows physicians and patients to easily tailor dosing as needed.
  • "GLOPERBA brings a new level of flexibility and control to the management of gout with colchicine," said Art Deas, CEO of Avion Pharmaceuticals.